Literature DB >> 17905431

Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience.

Massimo Breccia, Laura Cannella, Annamaria Frustaci, Caterina Stefanizzi, Anna Levi, Giuliana Alimena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17905431     DOI： 10.1016/j.leukres.2007.08.016

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  3 in total

1.  Comparative Assessment of Echocardiographic Patterns Among Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor and Healthy Controls.

Authors:  Abayomi O Bamgboje; Muheez A Durosinmi; Tuoyo O Mene-Afejuku; Micheal O Fagbayimu; Olusola Fajobi; Michael O Balogun
Journal:  Vasc Health Risk Manag       Date:  2022-02-15

Review 2.  First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.

Authors:  Guoqing Wei; Shamudheen Rafiyath; Delong Liu
Journal:  J Hematol Oncol       Date:  2010-11-26       Impact factor: 17.388

3.  Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies.

Authors:  Jessica Gordon; Robert Spiera
Journal:  Int J Rheumatol       Date:  2011-10-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.